(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization International Bureau



## 

(43) International Publication Date 24 December 2003 (24.12.2003)

**PCT** 

## (10) International Publication Number WO 03/105763 A2

(51) International Patent Classification7:

\_\_\_\_

**A61K** 

(21) International Application Number: PC

PCT/US03/18657

(22) International Filing Date:

13 June 2003 (13.06.2003)

(25) Filing Language:

English

(26) Publication Language:

**English** 

(30) Priority Data: 60/388,930

14 June 2002 (14.06.2002) US

(71) Applicant (for all designated States except US): AMYLIN PHARMACEUTICALS, INC. [US/US]; 9373 Towne Center Drive, San Diego, CA 92121 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): GEDULIN, Bronislava [US/US]; 14174 Half Moon Bay Drive, Del Mar, CA 92014 (US). YOUNG, Andrew, A. [NZ/US]; 1887

Caminito Velasco, La Jolla, CA 92037 (US). PATERNITI, James, R. Jr. [US/US]; 19833 Birch Bluff Avenue, San Diego, CA 92131 (US).

- (74) Agent: PERKINS COIE LLP; WISE, Michael J., CAN-DELORO, Carlos, Patent-LA, P.O. Box 1208, Seattle, WA 98111-1208 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: PREVENTION AND/OR TREATMENT OF INFLAMMATORY BOWEL DISEASE USING PYY OR AGONISTS THEREOF



or a PYY agonist is disclosed for treating a bowel condition such as inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), bowel atrophy, loss of bowel mucosa and loss of bowel mucosal function. The novel use is based on the discovery and demonstration that administration of PYY or a PYY agonist to an animal can protect the colon from injury induced by a hapten known to induce colitis.